Pharmaceutical Benefits Scheme criteria for the use of tumour necrosis factor-α inhibitors in the treatment of ankylosing spondylitis in Australia: Are they evidence based?

Internal Medicine Journal

Volumn 36, Issue 2, 2006, Pages 72-76

  Smith, M D ^a   Ahern, Michael J ^a  

^a REPATRIATION GENERAL HOSPITAL   (Australia)

Author keywords

Ankylosing spondylitis; Pharmaceutical Benefits Scheme; Tumor necrosis factor blockers

Indexed keywords

ACUTE PHASE PROTEIN; ANTINUCLEAR ANTIBODY; CORTICOSTEROID DERIVATIVE; DNA ANTIBODY; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; AUSTRALIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DISEASE DURATION; DRUG COST; DRUG SAFETY; EVIDENCE BASED MEDICINE; FUNCTIONAL STATUS; HUMAN; INJECTION SITE REACTION; LIVER DISEASE; MEDICAL LITERATURE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; AUSTRALIA; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOGLOBULIN G; PRESCRIPTIONS, DRUG; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33344472308     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2006.01004.x     Document Type: Review

References (13)

1. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis 2002; 61 Suppl III: iii8-18.
2. Dougados M, Dijkmans B, Khan M, Maksymowych W, van der Linden S, Brandt J. Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 2002; 61 Suppl III: iii40-50.
3. Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis. Arthritis Rheum 2005; 52: 1000-1008.
4. van der Heidje D, Dougados M, Davis J, Weisman MH, Maksymowych W, Braun J et al. Asessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of America recommendations for conducting trials in ankylosing spondylitis. Arthritis Rheum 2005; 52: 386-94.
5. Braun J, Sieper J. Biological therapies in the spondyloarthritides-the current state. Rheumatology (Oxford) 2004; 43: 1072-84.
6. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-93.
7. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005; 64: 229-34.
8. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis. Results of a randomized placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52: 582-91.
9. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48: 1667-75.
10. Gorman J, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 2002; 18: 1349-56.
11. Davis JC Jr, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO et al. for the Enbrel Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 3230-36.
12. Calin A, Dijkmans BAC, Emery P, Hakala M, Kalden J, Leirisalo-Repo M et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004; 63: 1594-1600.
13. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI50) to tumour necrosis factor α blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63: 665-70.